Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 21,580 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) CEO Alan H. Auerbach sold 21,580 shares of the business's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $3.54, for a total transaction of $76,393.20. Following the completion of the sale, the chief executive officer owned 7,180,901 shares in the company, valued at approximately $25,420,389.54. The trade was a 0.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Puma Biotechnology Price Performance

Shares of NASDAQ PBYI traded down $0.13 during mid-day trading on Friday, hitting $3.39. 300,719 shares of the company's stock traded hands, compared to its average volume of 414,487. The company's 50-day moving average is $3.37 and its two-hundred day moving average is $3.18. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43. The company has a market capitalization of $168.25 million, a P/E ratio of 4.40 and a beta of 1.29. Puma Biotechnology, Inc. has a 1 year low of $2.23 and a 1 year high of $4.13.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd.

Institutional Trading of Puma Biotechnology

Hedge funds have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its position in shares of Puma Biotechnology by 167.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,137 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 6,351 shares in the last quarter. Graham Capital Management L.P. bought a new position in Puma Biotechnology during the 4th quarter valued at about $33,000. ProShare Advisors LLC bought a new position in Puma Biotechnology during the 4th quarter valued at about $36,000. C2C Wealth Management LLC bought a new position in Puma Biotechnology during the 4th quarter valued at about $37,000. Finally, Causeway Capital Management LLC bought a new position in Puma Biotechnology during the 1st quarter valued at about $42,000. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.